Pharmaceutical Products: 70%
Medical Devices: 20%
Biotechnology: 10%

China: 60%
USA: 25%
Europe: 15%

Shenzhen Salubris Pharmaceuticals Co., Ltd. generates the majority of its revenue from the sale of pharmaceutical products, accounting for approximately 70% of total revenue. The medical devices sector contributes 20%, while the biotechnology sector makes up 10% of the revenue.

Geographically, China is the company's largest market, representing 60% of total revenue. The USA follows with 25%, while Europe accounts for 15% of the revenue. This distribution highlights the company's strong presence in the domestic market and the significant role of international markets, especially the USA and Europe.

Production Sites: Shenzhen, China; Hubei, China; Jiangsu, China

Shenzhen Salubris Pharmaceuticals Co., Ltd. mainly produces its products in China. The main production facilities are located in Shenzhen, Hubei, and Jiangsu. These sites are strategically chosen to serve both domestic demand and facilitate exports. The company continuously invests in modernizing and expanding its production capacities to meet the increasing market demands.

Focus on Research and Development: 12% of revenue (2024)

International Expansion: Target markets: USA and Europe

Diversification of Product Portfolio: Introduction of new biopharmaceuticals

Shenzhen Salubris Pharmaceuticals Co., Ltd. pursues a growth strategy that heavily emphasizes research and development. In 2024, the company invested 12% of its revenue in this area to develop innovative drugs and expand its product pipeline.

Another focus is on international expansion, particularly in the USA and Europe. These markets offer significant growth opportunities as the company aims to strengthen its presence outside of China.

Furthermore, Salubris is diversifying its product portfolio by introducing new biopharmaceuticals. This strategy aims to strengthen its market position and respond to the increasing demand for specialized medical solutions.

Main raw materials: Active pharmaceutical ingredients (APIs), excipients, packaging materials

Countries of origin: India, Germany, USA

Shenzhen Salubris Pharmaceuticals Co., Ltd. mainly imports active pharmaceutical ingredients (APIs) that are essential for the production of their medications. India is one of the largest suppliers of APIs worldwide and therefore plays a significant role as a country of origin for these raw materials.

In addition, excipients and packaging materials are imported from countries such as Germany and the USA, which are known for their high quality and reliability. These imports are crucial to ensure the high standards in the production and quality assurance of Salubris' pharmaceutical products.

Market share in China: 5% (estimated 2025)
R&D expenses: 10% of revenue (2024)
Patents: Over 200 active patents (2024)

Shenzhen Salubris Pharmaceuticals Co., Ltd. has a significant competitive advantage due to its strong presence in the Chinese pharmaceutical market, which is considered one of the largest globally. The company continuously invests in research and development, reflected in a high proportion of R&D expenses to revenue. These investments result in a robust pipeline of new products and innovations.

Additionally, Salubris has an extensive collection of patents that further strengthen its market position. These patents protect its innovative products and enable the company to stand out from the competition. The focus on innovative therapies and expansion into international markets could further enhance the competitive advantage.

Institutional Investor Share: Estimated 30-40% (2025)

Insider Buys/Sells: No specific data available (2025)

The institutional investor share in Shenzhen Salubris Pharmaceuticals Co., Ltd. is estimated to be around 30 to 40 percent. This estimate is based on typical industry values for comparable companies listed on the Shenzhen Stock Exchange.

There is no specific data available on insider buys or sells. Typically, companies disclose such information in their annual reports or through regulatory filings, which are not always immediately publicly accessible.

Market share of Shenzhen Salubris Pharmaceuticals Co., Ltd.: Estimated 3-5% (2025)

Top competitors and their market shares:

1. Sinopharm Group Co., Ltd.: 10-12%
2. Shanghai Pharmaceuticals Holding Co., Ltd.: 8-10%
3. China Resources Pharmaceutical Group Ltd.: 7-9%
4. CSPC Pharmaceutical Group Ltd.: 6-8%
5. Hengrui Medicine Co., Ltd.: 5-7%

Shenzhen Salubris Pharmaceuticals Co., Ltd. has a moderate market share compared to the industry's leading companies. The market share of 3-5% indicates that the company holds a significant but not dominant position in the market.

The moat of Shenzhen Salubris Pharmaceuticals could lie in specialized product lines and a strong R&D department, enabling the company to develop innovative drugs. This could be an advantage over some competitors who may rely more on generic products.

However, larger companies like Sinopharm and Shanghai Pharmaceuticals tend to have a stronger moat due to their comprehensive distribution networks, wider product ranges, and stronger financial resources. These factors allow them to defend and expand market shares more efficiently.

Overall, Shenzhen Salubris Pharmaceuticals has a certain strategic advantage through specialization and innovation, but the larger competitors are superior in terms of market presence and resources.

Revenue Growth: 8.5% (2024) R&D Expenses: 12% of revenue (2024) Market Share in China: 5% (2024)

Shenzhen Salubris Pharmaceuticals Co., Ltd. recorded a revenue growth of 8.5% in 2024, indicating solid demand for their pharmaceutical products. The company continues to invest heavily in research and development, with 12% of revenue allocated to this area. This suggests a strategic focus on remaining competitive in the long term through innovation and new products.

The 5% market share in China indicates that Salubris holds a significant position in the domestic market. This position could be further strengthened through ongoing investments in R&D and expansion into new therapeutic areas.

Overall, the financial and strategic orientation of the company suggests that it is well positioned to benefit from future growth opportunities. This could make the stock an attractive investment, especially for investors interested in long-term growth strategies.

Dividend Yield: 2.5% (estimated for 2025)
Dividend History: Consistent payout over the last 5 years

Shenzhen Salubris Pharmaceuticals Co., Ltd. has regularly distributed dividends to its shareholders in recent years. The estimated dividend yield for 2025 is around 2.5%, indicating a moderate but consistent payout policy.

Over the past five years, the company has demonstrated a reliable dividend history, pointing to a solid financial foundation and sustainable earnings power. This makes Salubris Pharmaceuticals' dividend attractive to investors who value regular income from their investments.